MX355366B - Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. - Google Patents

Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Info

Publication number
MX355366B
MX355366B MX2015004592A MX2015004592A MX355366B MX 355366 B MX355366 B MX 355366B MX 2015004592 A MX2015004592 A MX 2015004592A MX 2015004592 A MX2015004592 A MX 2015004592A MX 355366 B MX355366 B MX 355366B
Authority
MX
Mexico
Prior art keywords
recombinant virus
replication deficient
cytotoxic
deficient recombinant
response against
Prior art date
Application number
MX2015004592A
Other languages
English (en)
Inventor
Brinkmann Kay
Baur Karen
Hausmann Jürgen
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX355366B publication Critical patent/MX355366B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un virus de la vaccinia modificado recombinante Ankara (MVA) que codifica para al menos un antígeno y/o epítopo antigéncico, caracterizado porque la expresión del antígeno y/o epítopo antigénico está regulada por un elemento de control transcripcional que comprende al menos dos elementos que conducen la expresión temprana del antígeno y/o epítopo antigénico, y el elemento de control transcripcional es un promotor temprano /tardío que comprende la secuencia de nucleótidos de SEQ ID NO: 1 o una secuencia de nucleótidos que tiene al menos 90% de identidad con la secuencia de nucleótidos de SEQ ID NO: 1, y en donde el MVA recombinante expresa en células HeLa un nivel del antígeno codificado en presencia de 40 µg/ml de AraC que es al menos 50% del nivel del antígeno codificado en ausencia de AraC.
MX2015004592A 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. MX355366B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15985709P 2009-03-13 2009-03-13
EP09009759 2009-07-28
PCT/EP2010/001545 WO2010102822A1 (en) 2009-03-13 2010-03-11 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines

Publications (1)

Publication Number Publication Date
MX355366B true MX355366B (es) 2018-04-17

Family

ID=42115708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015004592A MX355366B (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
MX2011008791A MX2011008791A (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011008791A MX2011008791A (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Country Status (17)

Country Link
US (1) US8394385B2 (es)
EP (2) EP3456349A1 (es)
JP (2) JP2012520061A (es)
KR (1) KR101752737B1 (es)
CN (1) CN102341120B (es)
AU (1) AU2010223524A1 (es)
BR (1) BRPI1009138B1 (es)
CA (1) CA2751301C (es)
EA (1) EA023832B1 (es)
HK (1) HK1161677A1 (es)
IL (1) IL213572B (es)
MX (2) MX355366B (es)
MY (1) MY156997A (es)
NZ (1) NZ593525A (es)
SG (2) SG172115A1 (es)
WO (1) WO2010102822A1 (es)
ZA (1) ZA201106655B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
AU2015203893A1 (en) * 2009-03-13 2015-08-06 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
NZ608143A (en) 2010-10-15 2015-02-27 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
US10111946B2 (en) * 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
JP6505016B2 (ja) * 2012-10-28 2019-04-24 バヴァリアン・ノルディック・アクティーゼルスカブ 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
EP3119831B1 (en) 2014-03-21 2019-10-02 Furanix Technologies B.V Polyesters comprising 2,5-furandicarboxylate and saturated diol units having a high glass transition temperature
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
MX2018013340A (es) 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
JP7062003B2 (ja) 2016-09-28 2022-05-02 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN110168092A (zh) 2016-12-28 2019-08-23 特朗斯吉有限公司 溶瘤病毒和治疗分子
US11548980B2 (en) 2017-05-18 2023-01-10 Avantium Knowledge Centre B.V. Polyester copolymer
EP3625284A1 (en) 2017-05-18 2020-03-25 Avantium Knowledge Centre B.V. Polyester copolymer
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP7202362B2 (ja) 2017-08-24 2023-01-11 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
KR20200100745A (ko) 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP2022512595A (ja) 2018-10-05 2022-02-07 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
EP3883599A1 (en) 2018-11-20 2021-09-29 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
WO2020106144A1 (en) 2018-11-22 2020-05-28 Avantium Knowledge Centre B.V. Process for the production of one or more polyester copolymers, method for the preparation of one or more oligomers, oligomer composition and polyester copolymer
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
KR20220106775A (ko) 2019-11-20 2022-07-29 버베리안 노딕 에이/에스 암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
WO2023135313A1 (en) * 2022-01-17 2023-07-20 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0243029A1 (en) 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
US5747324A (en) 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2104649A1 (en) 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
CN100537773C (zh) 2000-11-23 2009-09-09 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
BR0214822A (pt) 2001-12-10 2004-12-14 Bavarian Nordic As Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis
KR20040108804A (ko) * 2002-05-16 2004-12-24 버베리안 노딕 에이/에스 우두 ａｔｉ 프로모터를 사용하는 것에 의한 변형백시니아 바이러스 안카라에서 유전자의 발현
EA012723B1 (ru) * 2002-11-25 2009-12-30 Бавариан Нордик А/С Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение
EP1845164B1 (en) 2003-11-24 2010-06-16 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus ankara
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

Also Published As

Publication number Publication date
WO2010102822A1 (en) 2010-09-16
IL213572B (en) 2018-05-31
IL213572A0 (en) 2011-07-31
MY156997A (en) 2016-04-15
CA2751301A1 (en) 2010-09-16
EP3456349A1 (en) 2019-03-20
JP6130876B2 (ja) 2017-05-17
CA2751301C (en) 2018-05-01
NZ593525A (en) 2012-12-21
KR101752737B1 (ko) 2017-06-30
BRPI1009138B1 (pt) 2022-04-05
EA023832B1 (ru) 2016-07-29
SG10201400593VA (en) 2014-06-27
US8394385B2 (en) 2013-03-12
CN102341120A (zh) 2012-02-01
EA201171128A1 (ru) 2012-08-30
SG172115A1 (en) 2011-07-28
US20100233203A1 (en) 2010-09-16
AU2010223524A1 (en) 2011-07-07
ZA201106655B (en) 2014-12-23
JP2012520061A (ja) 2012-09-06
EP2405939A1 (en) 2012-01-18
HK1161677A1 (zh) 2012-08-03
CN102341120B (zh) 2016-05-18
JP2015180216A (ja) 2015-10-15
MX2011008791A (es) 2011-09-29
BRPI1009138A2 (pt) 2016-03-08
KR20110129954A (ko) 2011-12-02

Similar Documents

Publication Publication Date Title
MX2011008791A (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
IL263249B (en) A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
TN2017000133A1 (en) Modified virus-like particles of cmv
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
TR201903223T4 (tr) Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
CA2763359C (en) New human rotavirus strains and vaccines
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
MY159543A (en) Recombinant avian influenza vaccine and uses thereof
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
WO2012118559A3 (en) Tetravalent and mixed head bivalent dengue vaccine
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2013173256A3 (en) New and improved influenza vaccines
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants
AR078147A1 (es) Regimen de inmunizacion por sensibilizacion - refuerzo heterologa
Dias et al. Study of the immune response induced by different adjuvants
TN2010000479A1 (en) Inactivated live - attenuated bluetongue virus vaccine
WO2008100142A3 (en) Vaccine formulation